Sanara Medtech Inc (NASDAQ: SMTI) is a medical technology company that markets and distributes surgical tissue repair products to surgeons at hospitals and surgical centers. Revenue is generated through direct product sales, primarily in the U.S. surgical tissue repair market. The company operates as a single reportable segment following the classification of its former wound care subsidiary, Tissue Health Plus (THP), as discontinued operations as of September 30, 2025. Headquartered in Fort Worth, Texas, in approximately 15,291 square feet of leased office space (as of December 31, 2025), Sanara's commercial portfolio includes CellerateRX Surgical, a Type I bovine hydrolyzed collagen for wound management; ALLOCYTE Plus, a cryopreserved viable cellular bone allograft; and FORTIFY TRG, a 510(k)-cleared small intestinal submucosa extracellular matrix graft for soft tissue reinforcement. The company holds 11 issued U.S. patents from assets acquired from Rochal Industries in July 2021, and in December 2023 signed an exclusive license with Tufts University covering 18 collagen peptides, forming subsidiary Sanara Collagen Peptides, LLC. As of April 2024, Sanara carries a senior secured term loan of up to $55.0 million with CRG Servicing LLC.

Revenue model

Transactional product sales of surgical tissue repair products to hospitals and surgical centers in the U.S. A royalty obligation flows outward to Tufts University based on net sales of licensed collagen peptide products through subsidiary Sanara Collagen Peptides, LLC.

Products and services

CellerateRX Surgical (Type I bovine hydrolyzed collagen for surgical and traumatic wound management); ALLOCYTE Plus (cryopreserved viable cellular bone allograft containing bone-derived progenitor cells and conformable bone fibers); FORTIFY TRG Tissue Repair Graft (freeze-dried, 510(k)-cleared small intestinal submucosa extracellular matrix sheet for soft tissue reinforcement); pipeline products under Sanara Collagen Peptides, LLC based on exclusive Tufts University license covering 18 collagen peptides.

Customers and end markets

Surgeons at hospitals and surgical centers. Primary end market is the U.S. surgical tissue repair market, with applications including spinal surgery wound management, orthoplastic limb preservation, hip arthroplasty, and gynecologic surgery.

Value-chain role

Sanara develops, markets, and distributes proprietary and licensed surgical products. It acquires technology through asset purchases (Rochal Industries, July 2021; Hymed Group and Applied Nutritionals, August 2023) and licensing (Tufts University, December 2023), then commercializes through a direct sales channel to hospital and surgical center customers. It does not own manufacturing facilities based on disclosed filing content.

Geographic exposure

United States. The 10-K filed 2026-03-24 describes products as sold primarily in the U.S. surgical tissue repair market. Office space is leased in Fort Worth, Texas.

Source: SEC 10-K, filed 2026-03-24

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Bioventus Inc Rxsight Inc United Health Products Inc OraSure Technologies Inc Retractable Technologies Inc VolitionRX Ltd SmileDirectClub, Inc. TELA Bio Inc Utah Medical Products Inc